PubMed:25839646 / 98-338 JSON TXT

Annnotations TAB JSON ListView MergeView

Id	Subject	Object	Predicate	Lexical cue
T14	47-59	3008	denotes	Cyclosporine
T16	47-61	D016572	denotes	Cyclosporine A
T17	47-61	D016572	denotes	Cyclosporine A
T19	63-66	PR:Q8CFD5	denotes	CsA
T20	63-66	PR:000007170	denotes	CsA
T22	63-66	P08796	denotes	CsA
T23	63-66	PR:Q13216	denotes	CsA
T21	63-66	CHEBI:55379	denotes	CsA
T18	63-66	D003057	denotes	CsA
T24	85-89	CHEBI:23888	denotes	drug
T25	122-131	UBERON:0001353	denotes	posterior
T26	132-139	GO:0042603	denotes	capsule
T27	132-139	UBERON:0003893	denotes	capsule
T28	132-153	D058442	denotes	capsule opacification
T29	132-153	D058442	denotes	capsule opacification
T30	155-158	D011085	denotes	PCO
T31	174-180	UBERON:0003674	denotes	canine
T33	217-220	PR:Q8CFD5	denotes	CsA
T34	217-220	PR:000007170	denotes	CsA
T36	217-220	P08796	denotes	CsA
T37	217-220	PR:Q13216	denotes	CsA
T35	217-220	CHEBI:55379	denotes	CsA
T32	217-220	D003057	denotes	CsA
T38	229-239	GO:0008219	denotes	cell death

Id	Subject	Object	Predicate	Lexical cue
T1	0-240	DRI_Approach	denotes	The purpose of this study was to determine the Cyclosporine A (CsA) dose and minimum drug delivery time needed to prevent posterior capsule opacification (PCO) in an ex vivo canine model and evaluate the mechanism of CsA-induced cell death.

Id	Subject	Object	Predicate	Lexical cue
T2	60-61	CVCL_6479\|Finite_cell_line\|Mus musculus	denotes	A
T3	99-103	CVCL_0047\|Telomerase_immortalized_cell_line\|Homo sapiens	denotes	time
T4	163-165	CVCL_8754\|Cancer_cell_line\|Homo sapiens	denotes	an
T5	163-165	CVCL_H241\|Cancer_cell_line\|Homo sapiens	denotes	an